Purpose Of Review: To describe some steps in the progress in the molecular biology of a peptide, apolipoprotein C3; its gene mutations that render individuals susceptible or resistant to developing hyperlipidaemia and atherosclerosis.
Recent Findings: Data that lead to the development of a new therapeutic agent volanesorsen.
Summary: The agent blocks the function of the mRNA of apolipoprotein C3 and successfully treats severe hypertriglyceridaemia in phase 3 trials (Ionis Pharmaceuticals).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MOL.0000000000000425 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!